SCHEMBL29400217

SCHEMBL29400217

CC(C)[C@H]1CC[C@]2(C)[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@@H]12

nearest known ligand 0.67

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.67
SLC10A1 Q14973 1/20 0.63
GPBAR1 Q8TDU6 4/20 0.61
PRKCD Q05655 1/20 0.61
NR1H4 Q96RI1 2/20 0.58
CES2 O00748 1/20 0.48
TOP2A P11388 1/20 0.48
CES1 P23141 1/20 0.48
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28453559 1.00 PTPN1 (0.67) PTPN1SLC10A1GPBAR1PRKCDNR1H4
SCHEMBL476921 0.81 SLC10A1 (0.73) PTPN1SLC10A1GPBAR1PRKCDNR1H4
SCHEMBL13384623 0.81 SLC10A1 (0.73) PTPN1SLC10A1GPBAR1PRKCDNR1H4
SCHEMBL476920 0.81 SLC10A1 (0.73) PTPN1SLC10A1GPBAR1PRKCDNR1H4
SCHEMBL13403268 0.81 SLC10A1 (0.73) PTPN1SLC10A1GPBAR1PRKCDNR1H4
SCHEMBL8068676 0.80 PTPN1 (1.00) PTPN1SLC10A1GPBAR1PRKCDNR1H4
SCHEMBL160601 0.80 PTPN1 (1.00) PTPN1SLC10A1GPBAR1PRKCDNR1H4
SCHEMBL17867237 0.79 SLC10A1 (0.55) PTPN1SLC10A1GPBAR1PRKCDNR1H4
SCHEMBL17388705 0.79 PTPN1 (0.57) PTPN1GPBAR1
SCHEMBL10061553 0.78 NR1H4 (0.74) PTPN1SLC10A1GPBAR1PRKCDNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724593-A2 POLYPEPTIDES FOR PREPARING TERPENOID COMPOUNDS Firmenich SA (CH) 2026-04-15 EP disclosed
EP-4724592-A2 PREPARATION OF TERPENOID COMPOUNDS Firmenich SA (CH) 2026-04-15 EP disclosed
US-20260043058-A1 SHC ENZYMES AND ENZYME VARIANTS GIVAUDAN SA (CH) 2026-02-12 US disclosed
US-20250361536-A1 SQUALENE HOPENE CYCLASE (SHC) VARIANTS GIVAUDAN SA (CH) 2025-11-27 US disclosed
US-12416027-B2 Squalene hopene cyclase (SHC) variants GIVAUDAN SA (CH) 2025-09-16 US disclosed
EP-4608876-A2 ENDOCYTIC AGENTS BioVentures, LLC (US) 2025-09-03 EP disclosed
US-12344531-B2 Silica with ultra-fast dissolution properties SIL'INNOV SRCL (BE) 2025-07-01 US disclosed
EP-4493685-A1 SHC ENZYMES AND ENZYME VARIANTS Givaudan SA (CH) 2025-01-22 EP disclosed
WO-2024256472-A2 PREPARATION OF TERPENOID COMPOUNDS FIRMENICH SA (CH) 2024-12-19 WO disclosed
US-20240368647-A1 ENZYMES AND APPLICATIONS THEREOF PROTEUS SA (FR) 2024-11-07 US disclosed
CN-116615555-A Enzymatic monocyclization of acyclic monoterpenes 斯图加特大学 2023-08-18 CN disclosed
US-20230220431-A1 ENZYMES AND APPLICATIONS THEREOF GIVAUDAN SA (CH) 2023-07-13 US disclosed
US-20230021613-A1 SQUALENE HOPENE CYCLASE (SHC) VARIANTS GIVAUDAN SA (CH) 2023-01-26 US disclosed
EP-4069836-A1 SQUALENE HOPENE CYCLASE (SHC) VARIANTS Givaudan SA (CH) 2022-10-12 EP disclosed
US-11466299-B2 Enzymes and applications thereof GIVAUDAN S.A. (CH) 2022-10-11 US disclosed
CN-115052982-A Squalene agamene cyclase (SHC) variants 奇华顿股份有限公司 2022-09-13 CN disclosed
US-11427476-B2 Mesoporous silicas and method for the synthesis thereof Sil'innov S.c.r.l. (BE) 2022-08-30 US disclosed
WO-2022106522-A1 ENZYMATIC MONOCYCLIZATION OF ACYCLIC MONOTERPENOIDS Universität Stuttgart (DE) 2022-05-27 WO disclosed
US-20220127650-A1 Process GIVAUDAN SA (CH) 2022-04-28 US disclosed
US-11261450-B2 Recombinant cell, method for producing recombinant cell, and method for producing isoprene or terpene SEKISUI CHEMICAL CO., LTD. (JP) 2022-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368647-A1 ENZYMES AND APPLICATIONS THEREOF HAO1, HLCS, HACL2 PTPN1 1674/4885SLC10A1 2726/4885GPBAR1 3868/4885
US-20260043058-A1 SHC ENZYMES AND ENZYME VARIANTS SQLE, DHCR7, CYP51A1 PTPN1 1232/4885SLC10A1 3875/4885GPBAR1 930/4885
US-20230220431-A1 ENZYMES AND APPLICATIONS THEREOF HAO1, HLCS, HACL2 PTPN1 1674/4885SLC10A1 2726/4885GPBAR1 3868/4885
US-11466299-B2 Enzymes and applications thereof HAO1, HLCS, HACL2 PTPN1 1674/4885SLC10A1 2726/4885GPBAR1 3868/4885
US-12344531-B2 Silica with ultra-fast dissolution properties SI, TREH, DDOST PTPN1 3729/4885SLC10A1 1408/4885GPBAR1 3770/4885
US-11427476-B2 Mesoporous silicas and method for the synthesis thereof LSS, SGMS2, SGMS1 PTPN1 3457/4885SLC10A1 2047/4885GPBAR1 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.